Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

25Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

Background: Immune checkpoint inhibitors have dramatically changed lung cancer treatment, demonstrating an overall survival benefit. There are limited data about re-challenge in patients with non-small cell lung cancer. We attempted to address this question for re-challenge of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. Methods: We retrospectively analyzed 11 patients with advanced non-small cell lung cancer treated with nivolumab and re-challenged with nivolumab/pemblorizumab at Kansai Medical University Hospital from December 2015 to December 2017. Results: Three patients achieved PR and two patients were in SD. These patients were apt to be good responders to the initial treatment, to develop immune-related adverse events and to be immediately started on re-challenge with immune checkpoint inhibitor. The median PFS was 2.7 (range, 0.5-16.1) months. Five patients (45%) had mild to moderate immune-related adverse events. Conclusion: Our study shows the effectiveness of re-challenge of immune checkpoint inhibitors in a subset of non-small cell lung cancer patients. Re-challenge might become one of treatment option for advanced non-small cell lung cancer.

Cite

CITATION STYLE

APA

Niki, M., Nakaya, A., Kurata, T., Yoshioka, H., Kaneda, T., Kibata, K., … Nomura, S. (2018). Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer. Oncotarget, 9(64), 32298–32304. https://doi.org/10.18632/oncotarget.25949

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free